Nicolas Hulscher, MPH
Focal Points Jan 16
Most Americans assume the "gene-based vaccine era" began with COVID-19. But few realize that a genetic vaccine platform has been deployed in food-producing animals for more than a decade — largely outside of public awareness or mainstream discussion.
In 2012, the USDA licensed Merck's SEQUIVITY® platform
for use in commercial swine herds. SEQUIVITY is marketed as an "RNA
particle" vaccine system designed to deliver genetic instructions so the
animal's cells produce targeted antigens. In other words: this is a
gene-based injection platform used in pigs raised for human consumption,
and it has been circulating in the U.S. pork production ecosystem since the early 2010s.
In a company statement, Merck said:
Millions of doses of the SEQUIVITY vaccine platform have safely been used by veterinarians in swine herds for more than ten years since the USDA first issued the license in 2012.It is also being used in other countries such as Canada, Chile, Mexico, and the Philippines.
This raises an obvious question: how many consumers would knowingly
accept gene-based vaccine platforms being injected into animals entering
the human food chain — without clear labeling, transparent public
discussion, or informed consent? Probably close to zero.
There
are no independent, long-term safety studies specifically designed to
assess residue/biomolecule persistence in edible tissues, downstream
consumer exposure, multi-generation or chronic outcomes, or robust
post-market adverse event transparency at scale.
RNA
particle-ridden pork will NOT Make America Healthy Again. Be cautious
with pork products — including bacon, ham, and sausage.
Nenhum comentário:
Postar um comentário